Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Omacetaxine Mepesuccinate

FDA-approved product (powder, subcutaneous), marketed as Synribo.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Omacetaxine Mepesuccinate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Other antineoplastic agents
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Omacetaxine Mepesuccinate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Omacetaxine Mepesuccinate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa

    NCT00004933 · start 2000-01

    Registered record
    Registry ID
    NCT00004933
    Conditions
    Leukemia
    Interventions
    hydroxyurea; Homoharringtonine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2000-01
    Completion
    2001-05
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    Interventionhydroxyurea; Homoharringtonine
    PhasePhase 3
    Registry statusTerminated

  • Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

    NCT00006364 · start 1999-11

    Registered record
    Registry ID
    NCT00006364
    Conditions
    Childhood Chronic Myelogenous Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Phase Chronic Myelogenous Leukemia; Relapsing Chronic Myelogenous Leukemia
    Interventions
    omacetaxine mepesuccinate; pharmacological study; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1999-11
    Completion
    Not recorded
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChildhood Chronic Myelogenous Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Phase Chronic Myelogenous Leukemia; Relapsing Chronic Myelogenous Leukemia
    Interventionomacetaxine mepesuccinate; pharmacological study; laboratory biomarker analysis
    PhasePhase 2
    Registry statusCompleted

  • Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase

    NCT00003694 · start 1999-03

    Registered record
    Registry ID
    NCT00003694
    Conditions
    Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Phase Chronic Myelogenous Leukemia
    Interventions
    omacetaxine mepesuccinate; cytarabine; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1999-03
    Completion
    Not recorded
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Phase Chronic Myelogenous Leukemia
    Interventionomacetaxine mepesuccinate; cytarabine; laboratory biomarker analysis
    PhasePhase 2
    Registry statusCompleted

  • Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

    NCT00003239 · start 1998-03

    Registered record
    Registry ID
    NCT00003239
    Conditions
    Leukemia
    Interventions
    Recombinant Interferon Alfa; Cytarabine; Omacetaxine Mepesuccinate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1998-03
    Completion
    2001-10
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    InterventionRecombinant Interferon Alfa; Cytarabine; Omacetaxine Mepesuccinate
    PhasePhase 2
    Registry statusCompleted

  • Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia

    NCT00030355

    Registered record
    Registry ID
    NCT00030355
    Conditions
    Leukemia
    Interventions
    homoharringtonine; chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    Interventionhomoharringtonine; chemotherapy
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn